AstraZeneca spins off new biotech company

Feb 28, 2018

AstraZeneca has created a new biotech company centered around six autoimmune disease treatments.

The $250 million company, called Viela Bio, will own three clinical and three pre-clinical compounds. One of the treatments targets a rare illness that impacts the optic nerve and spinal cord. The deal does not include a drug developed to treat lupus called anifrolumab, which is in final-stage clinical testing. 

The move comes as AstraZeneca looks to streamline its portfolio and shed non-core assets. But AstraZeneca will remain the largest minority stakeholder in the new company. 

Read the full Reuters report.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments